Teneberg S, Lönnroth I, Torres López J F, Galili U, Halvarsson M O, Angström J, Karlsson K A
Department of Medical Biochemistry, Göteborg University, Sweden.
Glycobiology. 1996 Sep;6(6):599-609. doi: 10.1093/glycob/6.6.599.
Glycoconjugates with terminal Gal alpha 3Gal beta 4GlcNAc beta sequences have been shown to be recognized by three carbohydrate-binding proteins; toxin A of Clostridium difficile, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13. However, the biological significance of this binding specificity in humans is unclear, since unsubstituted Gal alpha 3Gal beta 4GlcNAc beta sequences are not found in human tissues, due to suppression of the gene coding for the enzyme Gal beta 3-transferase. To explore this inconsistency, the binding of toxin A, human natural anti alpha-galactosyl IgG, and the Gal-13 monoclonal antibody to various glycosphingolipids was examined using the thin-layer chromatogram binding assay. The binding to Gal alpha 3Gal beta 4GlcNAc beta-terminated glycosphingolipids of rabbit erythrocytes was confirmed. A minor binding-active compound was also detected in the non-acid glycosphingolipid fraction of human erythrocytes. This glycosphingolipid was isolated and characterized by EI mass spectrometry, gas chromatography-EI mass spectrometry after degradation, and proton NMR spectroscopy, as GalNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer, corresponding to the x2 glycosphingolipid isolated before form this source. Two additional binding-active glycosphingolipids were found. One was GalNAc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4 Glc beta 1 Cer, produced from blood group A-active GalNAc alpha 3 (Fuc alpha 2) Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1 Cer by acid-induced defucosylation. The other was GlcNAc beta 3 Gal beta 4 GlcNAc beta 3 Gal beta 4 Glc beta 1 Cer, generated from NeuGc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer by enzymatic hydrolysis. A number of other glycosphingolipid sequences, including the human Le(x), Le(y), and I blood group determinants, suggested to act as receptors for toxin A, were not recognized by the three ligands. Despite the different terminal substituents and anomerity of the binding-active glycosphingolipids, calculated minimum energy conformations demonstrated topographical similarities in the spatial orientation of the terminal trisaccharides, possibly accounting for the cross-reactivity.
已显示具有末端Galα3Galβ4GlcNAcβ序列的糖缀合物可被三种碳水化合物结合蛋白识别;艰难梭菌毒素A、人天然抗α-半乳糖基IgG和单克隆抗体Gal-13。然而,这种结合特异性在人类中的生物学意义尚不清楚,因为由于编码Galβ3-转移酶的基因受到抑制,人组织中未发现未取代的Galα3Galβ4GlcNAcβ序列。为了探究这种不一致性,使用薄层色谱结合试验检测了毒素A、人天然抗α-半乳糖基IgG和Gal-13单克隆抗体与各种糖鞘脂的结合。证实了它们与兔红细胞中Galα3Galβ4GlcNAcβ末端糖鞘脂的结合。在人红细胞的非酸性糖鞘脂部分也检测到一种少量的结合活性化合物。通过电子轰击质谱、降解后的气相色谱-电子轰击质谱和质子核磁共振光谱对这种糖鞘脂进行了分离和表征,结果表明它是GalNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer,与之前从该来源分离出的x2糖鞘脂相对应。还发现了另外两种具有结合活性的糖鞘脂。一种是GalNAcα3Galβ4GlcNAcβ3Galβ4Glcβ1Cer,它是由血型A活性的GalNAcα3(Fucα2)Galβ4GlcNAcβ3Galβ4Glcβ1Cer经酸诱导去岩藻糖基化产生的。另一种是GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer,它是由NeuGcα3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer经酶促水解产生的。许多其他糖鞘脂序列,包括人Le(x)、Le(y)和I血型决定簇,被认为可作为毒素A的受体,但未被这三种配体识别。尽管具有结合活性的糖鞘脂的末端取代基和异头物不同,但计算出的最低能量构象表明末端三糖的空间取向在地形上具有相似性,这可能是交叉反应性的原因。